Tune in to this episode as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Dr. Jeremy Stuart, Senior Director of Genetics & Genomics at Medical University of South Carolina Health, discuss pharmacists' value as employees in clinical pharmacogenomics testing laboratories. Having employed pharmacists in his laboratories, Dr. Stuart will provide first-hand examples to illustrate how pharmacists have benefited his laboratories. Dr. Winslow and Dr. Sarrami will also share their real-world experiences working for clinical pharmacogenomics laboratories to help the laboratory achieve its goals.

After listening to this episode, the learner will be able to describe the responsibilities and roles pharmacists fulfill in clinical labs, name specific real-world examples that illustrate pharmacists’ contributions to pharmacogenomics in the clinical laboratory, and name education, training, and work experiences that prepare pharmacists to assume advanced practice roles in clinical laboratories.

Equitable biomarker testing access, including pharmacogenomics testing, is critical for patients to experience optimal medication therapy outcomes. Tune in to this episode as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Hilary Goeckner, Director of State & Local Campaigns - Access to Care of the American Cancer Society Cancer Action Network (ACS CAN), educate listeners about ACS CAN’s mission, how it executes on its mission, accomplishments, and future goals.  This episode is a must-listen for anyone who wants the latest update on the American Cancer Society Cancer Action Network’s work influencing state legislatures to pass legislation to expand coverage of biomarker testing, states that have already passed legislation, and those with pending legislation, and to learn how they too can advocate.  

After listening to this episode, listeners will be able to describe biomarker testing’s importance in healthcare; describe how the American Cancer Society Cancer Action Network is championing biomarker testing coverage legislation; name states that have passed biomarker testing legislation and those with pending legislation; know how one can contribute to the efforts to increase biomarker testing coverage.

 

Tune in to this episode as Dr. Becky Winslow and Dr. Megan Landsverk, Scientific Director of MolDX® and Chief Science Officer of Palmetto GBA®, discuss how laboratories may overcome the challenges they face in earning MolDX® coverage and reimbursement for their clinical pharmacogenomics tests. 

After listening to this episode, the learner will be able to define the relationship between Palmetto GBA®, MolDX®, the DEX Diagnostics® Exchange, and Technical Assessments; describe common errors clinical laboratories can avoid when designing and reporting their clinical PGx test panel that result in MolDX® not approving their technical assessment; prevent common claims submission errors that result in MolDX® denying clinical PGx test claims’ reimbursement; describe how MolDX® defines medical necessity for clinical PGx tests differently than they do non-PGx tests; and differentiate between MolDX®’s PGx policy and diagnostic genetic testing policies.